ClinicalTrials.gg
RecruitingNCT05844943Updated Oct 26, 2024

Early Feasibility Study of a Novel Negative Pressure Wound Therapy Glove for Hand Injuries

An interventional study of ReHeal glove with Negative Pressure Wound Therapy (NPWT) in Hand Injuries, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by University of Washington · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Hand Injuries with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Hand Injuries · United States.

Planned enrollment
21st of 26
10 · median 30
Started
2024
the only one that year
No phase
21 of 27
5 open now
Registered
23rd of 27
by date
Lead sponsor
2 of 27
University of Washington

Among the 27 studies in Hand Injuries with a site in United States, this one is the 21st largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 21 with no phase, and was the 23rd registered.

Hand Injuries

122 studies on the registry are indexed under Hand Injuries; 35 are open to participants now.

Browse Hand Injuries studies →

Open to participants now

8 of the 27 studies in Hand Injuries with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Hand Injuries studies recruiting now, 14 (54%) set no upper age limit and 10 (38%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hand Injuries with a site in United States, or all of them as a file.
02

Study summary

Single-center nonrandomized single-arm early feasibility study of participants with soft tissue trauma in the hand. Prior to enrolling participants with hand injuries, the safety of continuous glove use for up to 96 hours without a glove replacement will be assessed on healthy volunteers.

Injured participants will be on study for up to 7 weeks depending on when the final glove is removed.

Screening: Prior to surgery and through 72 hours post-surgery to identify eligible patients

Treatment with Glove: Treatment begins with initial application of the ReHeal Glove and can last up to 7 days (with dressing changes every 48-72 hours unless more frequent changes are requested by the treating physician.)

Follow-up: Up to 6 weeks after final removal of glove to ensure complete wound healing.

Read the detailed description

A maximum of 10 participants may be enrolled. Each participants will be enrolled sequentially, with in-depth review of study data from each individual participant before proceeding to the next participant. There will be one and only one participant at a time experiencing glove use. This allows the study team to identify and correct any safety issues before another participant is enrolled and begins glove use. This strategy is in place to minimize risk to participants. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.

Each participant will have the glove applied after surgery. The timing of the initial application could be immediately following surgery or up to 3 days after the surgery, at the discretion of the treating surgeon. Application delays of 1-3 days may be indicated if, in the opinion of the surgeon, the wound would benefit from a period of immobilization prior to donning the glove and allowing for the additional mobility possible with the glove dressing.

Reasons for a potential delay could include minimizing bleeding or oozing after debridement, or for protection of a skin graft. Following current standards of negative pressure wound therapy (NPWT), the wound will be assessed and the glove replaced every 48 to 72 hours. The glove may be assessed by the clinical care team and, if needed, removed and replaced earlier. At each participant encounter, data will be collected by the study team and pressure settings will be documented. At each study visit involving a dressing change, the glove will be removed for closer assessment of the wound and replaced with a new glove. Participants will remain in the study until wound healing or clinical resolution, or study exit. After study exit for each participant, data will be reviewed, and any design changes indicated by the results of the study will be implemented prior to enrollment of the next subject.

The ReHeal Glove and Cardinal Health Negative Pressure Wound Therapy Pro/Pro To Go pump will be used.

03

Conditions studied

  • Hand Injuries

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Persons 22 years or older

      • Wound size greater than 1cm2
      • Patient will have surgery to treat the wound, warranting the use of a dressing after surgery
      • Patient must be able to give
      • Persons who can read and write in English
      • Acute, unilateral, and isolated open finger or hand injuries caused by:

        • Burn
        • Blast
        • Abrasion
        • Avulsion
        • Amputation
        • Mangling hand injury
        • post-compartment syndrome release ((fasciotomy) and debridement
        • flexor tendon repair
        • exposed nerve or tendon
        • open wounds not yet ready for flap or graft
        • wounds after graft or flap
        • crush injuries associated with fractures (open or closed) which do not require stabilization and can therefore accommodate hand motion (for example, an abrasion injury may involve loss of some portion of cortical bone due to friction without losing structural stability sufficient to permit finger motion).
        • Fasciectomy
        • Tenolysis

Exclusion criteria

Exclusion Criteria:

    • Polytrauma outside of the hand

      • in the wound
      • Patient undergoing active chemotherapy
      • Hand wound with any untreated infection
      • Contaminated wounds not yet debrided
      • Insensate hand
      • Non-debrided tunneling wounds
      • Necrotizing soft-tissue infections
      • Osteomyelitis
      • Fractures requiring stabilization.
      • Untreated non-enteric fistulas
      • Smoker
      • Hemophiliac
      • Sepsis
      • Active cellulitis in the wound area
      • Radiation applied directly to the wound
      • Patients with allergies to product components: silicone, silicone adhesives and polyurethane films (direct contact with wounds), acrylic adhesives (direct contact with skin), polyethylene fabrics, and super-absorbent powders (polyacrylates within the dressing).
      • Patients chronically treated with any of the following medications:

        • Anti-coagulants
        • NSAIDs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Soft tissue hand injury

    Device: ReHeal glove with Negative Pressure Wound Therapy (NPWT)

Interventions

  • DeviceReHeal glove with Negative Pressure Wound Therapy (NPWT)

    ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).

06

What researchers measure

Primary outcomes

  1. Did significant adverse events occur

    Did infection or skin injury occur

    Time frame: 0-7 days

  2. Skin remains intact

    Did maceration occur.

    Time frame: 0-7 days

  3. Dressing changes

    Total number of dressing changes.

    Time frame: 0-7 days

  4. Additional adverse events

    Type and severity of adverse events.

    Time frame: 0-7 days

Secondary outcomes

  1. Hand Function (through range of motion)

    Total Active Motion of fingers

    Time frame: 7 days to 12 weeks

  2. Hand Function (through range of motion)

    Opposition of thumb

    Time frame: 7 days to 12 weeks

  3. Hand Function (grip and pinch strength)

    Grip and Pinch Strength

    Time frame: 7 days to 12 weeks

  4. Time to healing

    Wound closure rate will be assessed by documenting wound size at each clinic visit.

    Time frame: 7 days to 12 weeks

  5. Incidence of additional surgical procedure/interventions

    Where there any repeat debridement, skin grafts, flaps, or other procedures will be documented.

    Time frame: 7 days to 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2025, 10 months after the start.

Of 59 non-industry interventional studies with no phase under Hand Injuries, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 26. This study's planned 10 months is below that.

Counting every sponsor, half of 59 studies reached it within 14 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
May 6, 2023
StartActual
Aug 15, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 1, 2025
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844943
Responsible party
Christopher Allan (Associate Professor, School of Medicine, University of Washington) — Principal investigator
First posted
May 6, 2023
Start date
Aug 15, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Oct 26, 2024

Study contacts

Karen Adams
Contact
knadams1@uw.edu
206 354 3360
Christopher H Allan, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion